Navigating the Complex Terrain of Cancer Cachexia

Printer Friendly PagePrinter Friendly Page

Abstract

Cancer cachexia is a multifactorial syndrome characterized by loss of lean body mass, which may adversely affect a patient’s overall survival, quality of life, level of physical activity, and ability to receive antineoplastic therapy.1 Where full eradication of tumor burden is not achieved, multimodal prevention or treatment of cachexia is indicated. This article serves to highlight strategies to consider based on available evidence and treatment goals in cancer cachexia.

Introduction

Cachexia is a condition secondary to a primary disease process characterized by wasting, weight loss, muscle atrophy, fatigue, weakness, and loss of appetite in patients not actively trying to lose weight or making behavioral or lifestyle changes. It is estimated to be the cause of death in more than 30% of cancer patients, and more than half of all cancer patients have cachexia at the time of death.2 In advanced cancer, the prevalence of cachexia is thought to be between 60% and 80%.2
 
Precise percentages of cachexia prevalence are, however, difficult to capture due to the use of different criteria to define cachexia by the various reporting groups. Regardless, there is an urgent need to employ supportive care strategies that may effectively work to prevent or slow the development of cachexia and thereby improve treatment tolerance, response to treatment, quality of life, and overall survival.3

Classification of Cachexia Stages

A diagnostic framework developed in 2011 has been proposed that defines cancer cachexia as occurring along a continuum consisting of 3 stages: precachexia, cachexia, and refractory cachexia (Figure 1).4 The precachexia stage is classified as including anorexia, metabolic changes, and weight loss ≤5% in the previous 6 months.4 The cachexia stage is classified as involving weight loss >5% (or weight loss >2% if the patient has BMI<20 kg/m2 or sarcopenia) and often with decreased food intake and systemic inflammation.4 The refractory cachexia stage is classified as involving low performance status (ECOG score 3 or 4), prognosis of <3 months, and malignant disease that is both procatabolic and unresponsive to antineoplastic therapy.4 Proposed refinements have been made to the criteria of the precachexia stage, yet challenges persist in defining its parameters in a way that makes it a clinically relevant tool.5 The concept of precachexia, however, is important to grasp in that this is the stage at which metabolic changes have already begun to take place and progression to cachexia may be prevented by initiation of early interventions. This initial period of the cancer cachexia trajectory tends to be barely perceptible clinically and thus can be easily missed. Reversible risk factors should be addressed as early as possible on the continuum and must continue to be addressed through the cachexia stages. Identification of refractory cachexia is useful in determining when ethical considerations should be evaluated in the goals of naturopathic supportive care, and a shift to strictly palliative support should be discussed at that time.

Figure 1. The stages of cancer cachexia

 

Risk Factors, Pathophysiology, and Diagnostics

There are several risk factors for cancer cachexia, most of which are reversible if caught early enough (Figure 2). Risk factors include constipation, depression, inflammation, insulin resistance, male hypogonadism, low self-esteem, decreased appetite, and decreased food intake.1 In cancer patients, decreased appetite may be due to standard antineoplastic treatment–related toxicities such as dysgeusia, nausea and vomiting, odynophagia from mucositis, and early satiety after major abdominal surgical procedures. Psychosocial factors such as depression or increased stress also may contribute to decreased appetite. Cancer-related metabolic changes are considered a primary driving force behind decreases in appetite not due to treatment or psychosocial-related factors, which, along with loss of lean body mass, characterize the catabolic process associated with cachexia.1

Figure 2. Risk factors for cancer cachexia

 
Cancer-related metabolic changes include increases in muscle catabolism, resting energy expenditure, metabolism, cortisol, inflammatory cytokine production, and insulin resistance. While the governing process to these systemic catabolic changes remains unknown, recent evidence implicates a central nervous system role—namely chronic hypothalamic inflammation—as a possible source.6
 
Cachexia is characterized by lean muscle loss as the body shifts from an anabolic state to a catabolic state, progressive fatigue and weakness, and a decline in performance status. As fatigue and anorexia may manifest in cancer patients for various reasons, it is weight loss with decreased muscle strength that can help identify cachexia.1 Dynamometry or muscle strength testing may be employed for this assessment. However, more often, gross evaluation of strength is assessed through resistive force testing of the arms and upper legs by a clinician. 
 
Diagnostic lab markers may be used to identify the magnitude of cancer-related metabolic changes. These might include but are not limited to C-reactive protein (CRP), serum albumin, hemoglobin, TNF-alpha, IL-6, ghrelin, and leptin.1,7-10 Although no formal validated guidelines currently exist on specific parameters to diagnose cachexia, in 2008 it was proposed that any elevation seen in CRP or IL-6 or any decrease in hemoglobin or serum albumin might be used in combination with other parameters such as anorexia, fatigue, decreased muscle strength, and loss of lean body mass to arrive at a diagnosis of cachexia.9 A study of 136 male cancer patients in 2012 found that elevation of TNF-alpha and IL-6 independently predicted survival beyond cancer stage alone; however, the researchers found that low serum albumin alongside weight loss made use of parameters that were more readily available and that offered similar ability in predicting survival as compared to inflammatory markers.7 A 2014 study evaluated the utility of ghrelin and leptin in diagnosing cachexia and predicting survival. Researchers found that ghrelin levels above 663 ng/mL (sensitivity 83%; specificity 98%) and leptin levels below 31 ng/mL (sensitivity 79%; specificity 73%) were superior to the use of low albumin (sensitivity 63%; specificity 69.4%) in diagnosing cachexia and predicting survival.11 While laboratory biomarkers may be promising in the context of identifying the presence or magnitude of cachexia, values also may be abnormal due to other factors, and cachexia can sometimes be present without abnormalities in these markers. Their use therefore may have limited clinical value. 
 
A 2015 comprehensive review of 27 clinical trials on bioelectrical impedance analysis (BIA)/phase angle found that BIA/phase angle measurements “can benefit in the clinical management of cancer patients in multiple ways: in the prevention; diagnosis; prognosis; and outcomes related to treatments that affect nutritional and overall health status.”10 BIA measures resistance and reactance of electric current in body tissues. From these values, measures of total body water, fat-free mass, and fat mass can be derived. Phase angle is a measure derived directly from the resistance and reactance values and serves as an independent prognostic variable. A low phase angle correlates with increased malnutrition status, increased severity of disease, and lower overall survival. BIA measurements are of greatest utility when obtained at baseline and repeated throughout an individual’s course of treatment, measuring changes in an individual over time. In this way, the efficacy of management and predictive value of the longitudinal changes can be better determined so that supportive care strategies can be modified accordingly and aggressiveness of nutritional interventions increased or decreased as needed.10

Treatment of Cachexia

There is no better way to treat and reverse cachexia than to decrease the overall tumor burden, but in cases in which full eradication of tumor burden is not achieved, multimodal prevention or treatment of cachexia is indicated. Conventional methods beyond treating the cancer itself include pharmaceutical agents such as appetite stimulants (eg, megastrol acetate, dronabinol), steroids, testosterone, or nonsteroidal anti-inflammatory drugs. Studies have shown that a combination of integrative therapies has significantly improved outcomes in the treatment of cancer cachexia vs use of a single therapy alone.12-16 There is a consensus among experts that multimodal treatment (medication, nutrition, and other non-pharmaceutical strategies) to address the various contributing factors to cachexia should be offered to cancer patients in the precachexia and cachexia stages.17,18
A thoughtful approach should be taken in encouraging food choices that will both meet the protein and caloric intake goals and prevent worsening of other host conditions that contribute to cachexia progression. 
Nutritional counseling in cachexia typically focuses on increasing protein and caloric intake. Based on this nutritional approach as a single modality, evidence strongly suggests that early intervention in precachexia prior to CRP elevation can be effective in preventing or slowing weight loss.1,4,18 Evidence to suggest there is benefit of increased protein and caloric intake on physical function or quality of life once in the refractory cachexia stage is insufficient; however, nutritional counseling in this stage may be beneficial in helping the patient and caregivers understand the changes occurring and the limitations of nutrition during this time.18 Ultimately, once the systemic inflammatory response has begun, increased protein and caloric intake alone are inadequate to maintain weight as the inflammatory response dampens anabolism.1 In consideration of the implications of systemic inflammation along the cachexia continuum and the inability of increased protein and caloric intake alone to address the catabolic process, it is advised to continue encouraging anti-inflammatory food choices that also reduce oxidative stress and insulin resistance while providing essential nutrients even in the palliative care setting.19 A thoughtful approach should be taken in encouraging food choices that will both meet the protein and caloric intake goals and prevent worsening of other host conditions that contribute to cachexia progression. Although dietary approaches such as ketogenic diets and fasting are sometimes recommended for cancer patients, human clinical trial data on the effects of these specific strategies on the progression of cachexia in precachectic or cachectic cancer patients are not available at the time of this writing. However, consistent restriction (vs intermittent restriction) of calories or protein is suspected to worsen cachexia and is thus not advised for this patient population.
 
Exercise may attenuate the catabolic process of cachexia through several mechanisms, including decreasing insulin resistance, reducing inflammation, and modulating the breakdown of muscle mass.20 Though clinical trials of exercise therapy in defined cachectic cancer patient populations are lacking, a Cochrane review concluded there is strong rationale for the use of exercise in cancer cachexia.21 Multiple reviews and opinion articles have been published in support of exercise therapy as early intervention or prevention, as well as throughout more pronounced cachectic states.20,22-27 Both aerobic and resistance training have been shown to be beneficial in preclinical studies, although through different mechanisms. Aerobic activity lends more to attenuation of insulin resistance and inflammation, whereas resistance training exerts positive effects on lean muscle mass and strength.22-25 Arguments could be made for the encouragement of either form, or a combination of the 2, in the cachexia setting. Any specific recommendations should be made with consideration for the individual’s physical limitations, bone health and fracture risk, comorbidities, and preferences. Exercise tolerance may be decreased in patients with significant fatigue, anemia, or cardiac dysfunction. Care should be taken in tailoring exercise recommendations for these patients so as not to exacerbate these conditions.23
 
Non-pharmaceutical agents can be used in a multimodal approach that aims at preventing or treating cachexia. Often times, multipurpose supplemental agents such as those discussed in the following paragraphs will also prove useful for improving response to and tolerance of cancer treatments and can be continued throughout the long-term course of care. Use of nutritional, botanical, or vitamin supplements should include consideration of any potential interactions with antineoplastic therapies or medications, and use should be considered on an individual patient basis. Disease-specific and treatment-specific options should be considered in choosing targeted supplement support. For example, use of pancreatic enzymes may be a consideration in the setting of exocrine pancreatic insufficiency secondary to a pancreatic tumor or following resection of the involved malignant tissues. A standard naturopathic approach should also be taken in addressing an individual’s set of risk factors. The following is a look at some agents that may have a role in addressing some of the metabolic changes occurring in cachexia:
 
  • Amine supplementation may decrease proteolysis and increase protein synthesis in skeletal muscle.28 Creatine is an amine thought to improve skeletal muscle mass and function.29 It was administered in a double-blind, randomized, controlled trial that evaluated its effects on nutritional status, quality of life, and muscle function in 16 colorectal cancer patients. Participants took 5 g twice daily for the first week, followed by 2.5 g twice daily for 7 weeks. Results showed a significant improvement in phase angle after 8 weeks of creatine supplementation.30 Branched chain amino acids (BCAAs), consisting of leucine, isoleucine, and valine, have also been shown to be useful energy sources, protein synthesis stimulators, and anti-inflammatory agents.31-33  Small human trials suggest improvement in outcomes such as increased oral intake and increased protein metabolism and synthesis with the use of BCAAs in cancer patients.34-36
  • L-carnitine deficiency is thought to contribute to cancer cachexia progression.37 L-carnitine has been used in 2 randomized phase III clinical trials evaluating multimodal treatment in cancer cachexia, both of which showed improved outcomes in the combination-therapy arms.12,13 A placebo-controlled, randomized, double-blind multicenter trial evaluated the use of oral L-carnitine 4 g daily taken for 12 weeks by 26 advanced and irresectable pancreatic cancer patients. At the time of study enrollment, 88% of patients in the placebo group and 92% of patients in the L-carnitine group were receiving chemotherapy. Results showed statistically significant increased body mass index in the treatment arm vs a decrease in the control arm. A trend toward improved nutritional status and quality of life was also seen in the treatment arm.38
  • Omega-3 fatty acid supplementation has been widely reviewed for extensive clinical trial evidence supporting its utility in improving clinical outcomes in cancer.39-41  Reviews consistently suggest that increased quality of life, increased physical activity, improved response to chemotherapy, and decreased inflammation are among the benefits of omega-3 fatty acid supplementation in cancer patients. In the latest review, authors concluded that omega-3 fatty acids, when used as part of a multimodal strategy, are effective in cachexia.41 In a randomized, controlled, crossover trial of 20 healthy subjects to evaluate the effects on appetite of 3 g EPA+DHA taken daily for 3 weeks, results were significant for less postprandial sensation of fullness in both genders and, in women, a significant increase in desire to eat with use of fish oil supplementation.42 A randomized controlled trial (N=68) comparing the daily use of a standard protein- and energy-dense nutritional formula to a comparable one enriched with omega-3 fatty acids (7.24 g daily), probiotics, and additional micronutrients showed a statistically significant (P<0.05) increase in body weight in cachectic head and neck cancer patients undergoing an 8-week course of radiation treatment when the omega-3 fatty acid–enriched formula was used during and 1 month after their radiation course vs the standard formula.43 A single-arm phase II study evaluating the use of combination therapy taken daily for 4 months consisting of antioxidants, a nutritional formula enriched with omega-3 fatty acids (3.12 g EPA+DHA per day), medroxyprogesterone acetate, and celecoxib showed significant improvement in body weight, lean body mass and appetite in the 39 patients with advanced cancer who presented at baseline with cancer-related anorexia/cachexia.14 In a phase III randomized study, 332 patients with cancer-related anorexia/cachexia were assigned to 1 of 5 treatment arms: arm 1, medroxyprogesterone or megestrol acetate; arm 2, oral EPA-enriched nutritional formula (2.2 g of EPA daily); arm 3, L-carnitine; arm 4, thalidomide; arm 5, a combination of therapies used in arms 1-4. Treatment was of 4 months’ duration, and results showed superiority of arm 5 over the other treatment arms, with a significant increase in lean body mass, decrease in resting energy expenditure, improvement in fatigue, increase in appetite, decrease in IL-6 and TNF-alpha, and improvement in performance status.12
  • Melatonin has been shown in clinical trials to be beneficial for cancer patients receiving chemotherapy, radiation, supportive care, or palliative care and to possibly increase overall survival when used as part of a multimodal strategy. The research suggests melatonin has antioxidant, antiproliferative, and immune-modulating effects and also decreases the intensity of chemotherapy-induced side effects.44 In regards to cachexia specifically, results of a small clinical trial evaluating melatonin in combination with fish oil showed that the combination had a weight-stabilizing effect in cachectic patients.45 Results of another clinical trial evaluating melatonin in combination with supportive care vs supportive care alone in patients with metastatic solid tumor showed decreased rate of weight loss in the combination arm.46 A randomized, double-blind, placebo-controlled study evaluating melatonin as a single therapy for cachexia was conducted in patients with advanced cancer but terminated after only 28 days due to lack of significant differences seen between treatment arms in weight, appetite, and quality of life parameters.47 However, the authors note that 32% of their patients did not complete the trial due to advanced disease and further suggest that melatonin may have had a more significant role if not initiated so late in the disease trajectory.
 
Other supplements that may be worth consideration as part of a multimodal approach in the prevention or treatment of cachexia include vitamin D,19,48 magnesium,49 antioxidant therapies,50 and anti-inflammatory agents such as curcumin,19 quercetin,51 and boswellia.19 These may further address some of the underlying metabolic changes in cancer cachexia; however, they have been less researched for this specific purpose in cachectic patient populations. 

Conclusion

Navigating the complex terrain of cancer cachexia can be done strategically and may improve treatment tolerance, response to treatment, quality of life, and overall survival. As always, physicians must take into consideration all factors relating to the individual patient including but not limited to diagnosis, prognosis, involved sites of disease, symptoms, physical limitations, treatment and related side effects, psychosocial circumstances, socioeconomic factors, cultural and religious backgrounds, and patient preferences. Identifying early on a patient’s risk factors for cachexia and addressing them then may slow or reverse the progression of refractory cachexia. Taking action on nutritional, exercise, or supplement recommendations should always be patient-driven, and caregivers should be counseled accordingly. Understanding and communicating the limitations of naturopathic support therapies when they are initiated late in the course of the cachexia trajectory can reduce unrealistic expectations and decrease burdens on patients and caregivers while educating them on the changes that are occurring.52,53 While ongoing and future clinical trials on multimodal treatments for cancer cachexia are much needed and may help us to achieve improvements in outcomes such as quality of life and overall survival for our patients, the synthesis of currently available evidence this article provides serves as a basis and call for routinely employing an integrated approach in an effort to diminish the suffering experienced by those who are at risk for or affected by cancer cachexia.

About the Author

Rebecca Lovejoy, ND, LAc, received her master's degree from the Tri-State College of Acupuncture in New York City and her naturopathic medical degree from the Southwest College of Naturopathic Medicine in Tempe, Arizona. Following completion of a 2-year hospital-based residency in naturopathic oncology at the Indiana University Health Goshen Center for Cancer Care, she joined the staff, with delight, where she currently continues as a proud member of the integrative care team.

References

  1. Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:601434. 
  2. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1(1):1-5. 
  3. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):261-263.
  4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-495.
  5. Blauwhoff-Buskermolen S, de van der Schueren MA, Verheul HM, Langius JA. 'Pre-cachexia': a non-existing phenomenon in cancer? Ann Oncol. 2014;25(8):1668-1669. 
  6. Burfeind KG, Michaelis KA, Marks DL. The central role of hypothalamic inflammation in the acute illness response and cachexia. Semin Cell Dev Biol. 2015 Nov 3. pii: S1084-9521(15)00245-1. 
  7. Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle. 2012;3(4):245-251. 
  8. Bilir C, Engin H, Can M, Temi YB, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol. 2015;32(3):56. 
  9. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793-799. 
  10. Grundmann O, Yoon SL, Williams JJ. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients-a comprehensive review. Eur J Clin Nutr. 2015;69(12):1290-1297. 
  11. Mondello P, Lacquaniti A, Mondello S, et al. Emerging markers of cachexia predict survival in cancer patients. BMC Cancer. 2014;14:828. 
  12. Mantovani G, Macciò A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15(2):200-211. 
  13. Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol. 2012;124(3):417-425.
  14. Mantovani G, Macciò A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15(5):1030-1034. 
  15. Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer. 2007;59(1):14-20.
  16. Kanat O, Cubukcu E, Avci N, et al. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori. 2013;99(2):229-233. 
  17. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44(8):1124-1132.
  18. Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen, Department of Palliative Medicinen/European Palliative Care Research Collaborative; 2010. Available at: http://www.epcrc.org/publication_listfiles.php?id=mWdBCMI5eXVlcNFk7Gnq. Accessed February 9, 2016.
  19. Bazzan AJ, Newberg AB, Cho WC, Monti DA. Diet and nutrition in cancer survivorship and palliative care. Evid Based Complement Alternat Med. 2013;2013:917647. 
  20. Maddocks M, Murton AJ, Wilcock A. Therapeutic exercise in cancer cachexia. Crit Rev Oncog. 2012;17(3):285-292.
  21. Grande AJ, Silva V, Riera R, et al. Exercise for cancer cachexia in adults. Cochrane Database Syst Rev. 2014;11:CD010804. 
  22. Khamoui AV, Kim JS. Candidate mechanisms underlying effects of contractile activity on muscle morphology and energetics in cancer cachexia. Eur J Cancer Care (Engl). 2012;21(2):143-157.
  23. Argilés JM, Busquets S, López-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle. 2012;3(2):73-76.
  24. Ormsbee MJ, Prado CM, Ilich JZ, et al. Osteosarcopenic obesity: the role of bone, muscle, and fat on health. J Cachexia Sarcopenia Muscle. 2014;5(3):183-192.
  25. Gould DW, Lahart I, Carmichael AR, Koutedakis Y, Metsios GS. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle. 2013;4(2):111-124.
  26. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90-99.
  27. Alves CR, da Cunha TF, da Paixão NA, Brum PC. Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. 2015;125:9-14.
  28. de Campos-Ferraz PL, Andrade I, das Neves W, Hangai I, Alves CR, Lancha AH Jr. An overview of amines as nutritional supplements to counteract cancer cachexia. J Cachexia Sarcopenia Muscle. 2014;5(2):105-110.
  29. Gualano B, Artioli GG, Poortmans JR, Lancha Junior AH. Exploring the therapeutic role of creatine supplementation. Amino Acids. 2010;38(1):31-44. 
  30. Norman K, Stübler D, Baier P, et al. Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer—a double blind randomized controlled trial. Clin Nutr. 2006;25(4):596-605. 
  31. Nicastro H, Artioli GG, Costa Ados S, et al. An overview of the therapeutic effects of leucine supplementation on skeletal muscle under atrophic conditions. Amino Acids. 2011;40(2):287-300.
  32. Nicastro H, da Luz CR, Chaves DF, et al. Does branched-chain amino acids supplementation modulate skeletal muscle remodeling through inflammation modulation? Possible mechanisms of action. J Nutr Metab. 2012;2012:136937.
  33. Shimomura Y, Yamamoto Y, Bajotto G, et al. Nutraceutical effects of branched-chain amino acids on skeletal muscle. J Nutr. 2006;136(2):529S-532S.
  34. Tayek JA, Bistrian BR, Hehir DJ, Martin R, Moldawer LL, Blackburn GL. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer. 1986;58(1):147-157. 
  35. Yamanaka H, Kanemaki T, Tsuji M, et al. Branched-chain amino acid-supplemented nutritional support after gastrectomy for gastric cancer with special reference to plasma amino acid profiles. Nutrition. 1990;6(3):241-245.
  36. Le Bricon T. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. Clin Nutr. 1996;15(6):337.
  37. Malaguarnera M, Risino C, Gargante MP, et al. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol. 2006;12(28):4541-4545.
  38. Kraft M, Kraft K, Gärtner S, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)—a randomized multicentre trial. Nutr J. 2012;11:52.
  39. Baracos VE, Mazurak VC, Ma DW. n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev. 2004;17(2):177-192.
  40. van der Meij BS, van Bokhorst-de van der Schueren MA, Langius JA, Brouwer IA, van Leeuwen PA. n-3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation. Am J Clin Nutr. 2011;94(5):1248-1265.
  41. Nabavi SF, Bilotto S, Russo GL, et al. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. Cancer Metastasis Rev. 2015;34(3):359-380.
  42. Damsbo-Svendsen S, Rønsholdt MD, Lauritzen L. Fish oil-supplementation increases appetite in healthy adults. A randomized controlled cross-over trial. Appetite. 2013;66:62-66.
  43. Yeh KY, Wang HM, Chang JW, et al. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(1):41-48.
  44. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293-303.
  45. Persson C, Glimelius B, Rönnelid J, Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition. 2005;21(2):170-178.
  46. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer. 1996;32A(8):1340-1343. 
  47. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31(10):1271-1276.
  48. Del Fabbro E, Hui D, Dalal S, Dev R, Nooruddin ZI, Bruera E. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med. 2011;14(9):1004-1008. 
  49. Caddell JL. Geriatric cachexia: a role for magnesium deficiency as well as for cytokines? Am J Clin Nutr. 2000;71(3):851-853. 
  50. Mueller TC, Burmeister MA, Bachmann J, Martignoni ME. Cachexia and pancreatic cancer: are there treatment options? World J Gastroenterol. 2014;20(28):9361-9373. 
  51. Le NH, Kim CS, Park T, et al. Quercetin protects against obesity-induced skeletal muscle inflammation and atrophy. Mediators Inflamm. 2014;2014:834294. 
  52. Oberholzer R, Hopkinson JB, Baumann K, et al. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage. 2013;46(1):77-95. 
  53. Reid J. Psychosocial, educational and communicative interventions for patients with cachexia and their family carers. Curr Opin Support Palliat Care. 2014;8(4):334-338.